Friday, January 3, 2025
1/3/2025
Abstract Hypertension is an enormous health and socio-economic burden in the United States and is a leading cause of cardiovascular morbidity and mortality worldwide. Overall, 1 in 3 of Americans have hypertension, and nearly 2 in 3 of Americans over the age of 65 years. Hypertension significantly increases the risk of developing heart failure (HF), whereas reducing blood pressure decreases the risk. It is known that hypertension is the most common risk factor in the development of HF with preserved ejection fraction (HFpEF) by a mechanism where systemic inflammation and activation of reactive oxygen species reduces nitric oxide bioavailability and impairs Protein kinase G (PKG) signaling. Chronic hypertension is characterized by impaired systolic and diastolic cardiac function and pathological remodeling, and excessive renal sodium retention and volume overload, which together contribute to progression to HFpEF and a poor prognosis. Therapies attempting to reduce blood pressure in HFpEF patients have mostly failed to yield positive results. Many patients have hypertension that is resistant to conventional therapy, and because the majority of HFpEF patients are elderly, they display aging inherent deficits in nitric oxide bioavailability and PKG signaling that make available therapies less effective. Although, it is known that impaired PKG signaling is central to the cardio-renal deficits related to hypertension especially in older individuals, therapies specifically designed to enhance PKG activity have not been successful. Our preliminary studies have explored an alternative approach to manipulating PKG levels to improve outcomes in hypertension and HFpEF by bypassing complex signaling cascades in favor of directly targeting the downstream effectors of PKG. We have identified a phosphorylatable serine residue 273 (S273) in the regulatory protein MyBPC as a critical specific downstream target of PKG that is upregulated in various models of pressure overload-induced hypertension, but is downregulated in models of HFpEF. These observations lay the foundation for our general hypothesis that increasing S273 phosphorylation levels in chronic Htn prevents progression to HFpEF. In Aim 1 we will define the PKG-specific in vitro molecular mechanisms of S273 phosphorylation, in Aim 2 we will utilize experimental models of hypertension and HFpEF and novel transgenic animal models to determine the in vivo functional consequences of altered PKG levels and aging, and in Aim 3 we will utilize in vivo cardioselective AAV9 viral gene delivery of phosphomimetic S273 to prevent or reverse the HFpEF phenotype in aged mice and in mice with ablated PKG. Successful completion of these mechanistic studies have the promise to identify S273 as a novel therapeutic strategy to treat hypertension-induced HFpEF, a devastating disease with no effective treatments.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).